Radiopharmaceutical CDMO/CMO Services Market-By Service Type :
Radiopharmaceutical CDMO/CMO Services Market-By Modality:
Radiopharmaceutical CDMO/CMO Services Market -By Radionuclide Type:
Radiopharmaceutical CDMO/CMO Services Market -By Radio Conjugate Type:
Radiopharmaceutical CDMO/CMO Services Market -By Development Stage:
Radiopharmaceutical CDMO/CMO Services Market -By End-User / Sponsor Type:
Radiopharmaceutical CDMO/CMO Services Market -By Facility / Capability Type:
Radiopharmaceutical CDMO/CMO Services Market -By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Radiopharmaceutical CDMO/CMO Services Market Snapshot
Chapter 4. Global Radiopharmaceutical CDMO/CMO Services Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
Chapter 5. Market Segmentation 1: By Manufacturing Source Estimates & Trend Analysis
5.1. By Manufacturing Source & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Manufacturing Source:
5.2.1. Nuclear Reactors
5.2.2. Cyclotrons
Chapter 6. Market Segmentation 2: By Manufacturing Source Estimates & Trend Analysis
6.1. By Application & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
6.2.1. Diagnostic Radiopharmaceuticals
6.2.1.1. Positron Emission Tomography Radiopharmaceuticals
6.2.1.2. SPECT Radiopharmaceuticals
6.2.2. Therapeutic Radiopharmaceuticals
6.2.2.1. Alpha Emitters
6.2.2.2. Beta Emitters
6.2.2.3. Other Therapeutic Radiopharmaceuticals
Chapter 7. Market Segmentation 3: By Operation Scale Estimates & Trend Analysis
7.1. By Operation Scale & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Operation Scale:
7.2.1. Preclinical
7.2.2. Clinical
7.2.3. Commercial
Chapter 8. Market Segmentation 4: By Radioisotope Estimates & Trend Analysis
8.1. By Radioisotope & Market Share, 2024 & 2034
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Radioisotope:
8.2.1. Technetium-99m
8.2.2. Fluorine-18
8.2.3. Leutetium-177
8.2.4. Gallium-68
8.2.5. Actinium-225
8.2.6. Other Radioisotopes
Chapter 9. Market Segmentation 5: By Therapeutic Area Estimates & Trend Analysis
9.1. By Therapeutic Area & Market Share, 2024 & 2034
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
9.2.1. Cardiovascular Disorders
9.2.2. Neurological Disorders
9.2.3. Oncology
9.2.4. Other Therapeutic Area
Chapter 10. Radiopharmaceutical CDMO/CMO Services Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.1.2. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.1.3. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.1.4. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.1.5. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.1.6. North America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.1.6.1. U.S.
10.1.6.2. Canada
10.2. Europe
10.2.1. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.2.2. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.2.3. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.2.4. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.2.5. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.2.6. Europe Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.2.6.1. Germany
10.2.6.2. Denmark
10.2.6.3. Turkey
10.2.6.4. Romania
10.2.6.5. Bulgaria
10.2.6.6. Austria
10.2.6.7. Norway
10.2.6.8. Rest of Europe
10.3. Asia Pacific
10.3.1. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, 2021-2034
10.3.2. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, 2021-2034
10.3.3. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.3.4. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.3.5. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.3.6. Asia Pacific Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.3.6.1. China
10.3.6.2. Australia
10.3.6.3. Taiwan
10.3.6.4. South Korea
10.3.6.5. Thailand
10.3.6.6. Rest of Asia Pacific
10.4. Latin America
10.4.1. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, (US$ Million) 2021-2034
10.4.2. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, (US$ Million) 2021-2034
10.4.3. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.4.4. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.4.5. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.4.6. Latin America Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.4.6.1. Brazil
10.4.6.2. Rest of Latin America
10.5. Middle East & Africa
10.5.1. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Manufacturing Source, (US$ Million) 2021-2034
10.5.2. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Application, (US$ Million) 2021-2034
10.5.3. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Operation Scale, 2021-2034
10.5.4. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Radioisotope, 2021-2034
10.5.5. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034
10.5.6. Middle East & Africa Radiopharmaceutical CDMO/CMO Services Market revenue (US$ Million) estimates and forecasts by Country, 2021-2034
10.5.6.1. Kuwait
10.5.6.2. U.A.E.
10.5.6.3. Egypt
10.5.6.4. Rest of MEA
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1 NorthStar Medical Radioisotopes
11.2.1.1 Business Overview
11.2.1.2 Key Product /Service Overview
11.2.1.3 Financial Performance
11.2.1.4 Geographical Presence
11.2.1.5 Recent Developments with Business Strategy
11.2.2 Nucleus RadioPharma
11.2.3 Evergreen Theragnostics
11.2.4 SpectronRx
11.2.5 PharmaLogic
11.2.6 Cardinal Health
11.2.7 SOFIE Biosciences
11.2.8 POINT Biopharma (Lantheus)
11.2.9 BWXT Medical
11.2.10 GE Healthcare
11.2.11 Ratio Therapeutics
11.2.12 RadioMedix
11.2.13 Viewpoint Molecular Targeting
11.2.14 AtomVie Global Radiopharma
11.2.15 Fusion Pharmaceuticals
11.2.16 Isologic Innovative Radiopharmaceuticals
11.2.17 Nordion
11.2.18 TRIUMF Innovations
11.2.19 ITM Isotope Technologies Munich SE
11.2.20 Eckert & Ziegler
11.2.21 Bayer
11.2.22 Curium Pharma
11.2.23 ITM Radiopharma GmbH
11.2.24 Theragnostics Ltd.
11.2.25 Quotient Sciences
11.2.26 Advanced Accelerator Applications (Novartis)
11.2.27 Orano Med
11.2.28 Cyclopharma Laboratories
11.2.29 ITEL Pharma
11.2.30 IRE-ELiT
11.2.31 Cyclotron Company
11.2.32 SCK CEN
11.2.33 Minerva Imaging
11.2.34 Isotopia Molecular Imaging
11.2.35 Eczacıbaşı-Monrol Nuclear Products
11.2.36 Nihon Medi-Physics
11.2.37 FUJIFILM Toyama Chemical
11.2.38 Canon Healthcare
11.2.39 Dongcheng Pharmaceutical Group
11.2.40 Sinotau Pharmaceutical Group
11.2.41 FutureChem
11.2.42 DuChemBio
11.2.43 Telix Pharmaceuticals
11.2.44 ANSTO Health
11.2.45 Cyclotek
11.2.46 Global Medical Solutions
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.